Asterisks * preceding page numbers refer to studies using human-derived material.


5 Activation of the gadd153 Promoter by Genotoxic Agents: A Rapid and Specific Response to DNA Damage. Jennifer D. Luetby and Nikki J. Holbrook.

11 Abundance of the Primary Transcript and Its Processed Product of Growth-related Genes in Normal and Leukemic Cells during Proliferation and Differentiation. Sergio Ferrari, Enrico Tagliafico, Rossella Manfredini, Alexis Grande, Elena Rossi, Patrizia Zucchini, Giuseppe Torelli, and Umberto Torelli.


36 Intracellular Metabolism of 5-Formyl Tetrahydrofolate in Human Breast and Colon Cell Lines. Donna M. Boarman and Carmen J. Allegra.


121 Immunotherapy of Human Gliona Xenografts with Unlabeled, 131I-, or 125I-labeled Monoclonal Antibody 425 to Epidermal Growth Factor Receptor. Hans Bender, Hiroshi Takahashi, Koji Adachi, Paul Belser, Shao-hong Liang, Marie Prewett, Martin Schrappe, Arne Sutter, Ulrich Rodeck, and Dorothee Herlyn.


138 Melphalan Penetration of the Blood-Brain Barrier via the Neutral Amino Acid Transporter in Tumor-bearing Brain. Eain M. Cornford, Deborah Young, James W. Paxton, Graeme J. Finlay, William R. Wilson, and William M. Pardridge.

§ The CONTENTS arranged by Subject Category can be found immediately following these CONTENTS.


154 Effect of ω3 and ω6 Fatty Acids on Transformation of Cultured Cells by Irradiation and Transfection. Mareyuki Takahashi, Marek Przetakiewicz, Augustine Ong, Carmia Borek, and John M. Lowenstein.


168 Morphological Reversion of sis-transformed NIH3T3 Cells by Trichostatin A. Kenji Sugita, Kenzo Koizumi, and Hiroshi Yoshida.


*187 Increased Sensitivity of Human Keratinocytes Immortalized by Human Papillomavirus Type 16 DNA to Growth Control by Retinoids. Lucia Pirisi, Ayse Batova, G. Ronald Jenkins, John R. Hodam, and Kim E. Creek.


202 Specific Binding to Protein Kinase C by Ingenol and Its Induction of Biological Responses. Clare M. Hasler, Geza Acs, and Peter M. Blumberg.

*209 Relative Activity of Structural Analogues of Amsacrine against Human Leukemia Cell Lines Containing Amsacrine-sensitive or -resistant Forms of Topoisomerase II: Use of Computer Simulations in New Drug Development. Leonard A. Zwwelling, Michael J. Mitchell, Patricia Satimunwaycha, Janice Mayes, Elizabeth Aitschuler, Michael Hinds, and Bruce C. Baguley.

**Cancer Research**

**VOLUME 52 • NUMBER 1**

**CONTENTS Arranged by Subject Category**

---

**Advances in Brief**

* 218 Altered p53 Gene Structure and Expression in Human Epithelial Cells after Exposure to Nickel. L. Mahle, R. A. Metcalf, D. Ryberg, W. P. Bennett, C. C. Harris, and A. Haugen.

* 222 Suppression of Acute Lymphoblastic Leukemia by the Human Wild-Type p53 Gene. Jian Cheng, Jiing-Kuan Yee, Jo Yeargin, Theodore Friedmann, and Martin Haas.


* 231 Role of Tamoxifen in the Induction of Hormone-independent Rat Mammary Tumors. Karin C. Fendl and Stephen J. Zimpinski.

---

**BASIC SCIENCES**

**Biochemistry and Biophysics**


* 58 Nitroreductases and Glutathione Transferases That Act on 4-Nitroquinoline 1-Oxide and Their Differential Induction by Butylated Hydroxyanisole in Mice. J. Steven Stanley, J. Lyndal York, Nikkii J. Holbrook.


* 95 Identification of the Major Protein Components in Breast Secretions from Women with Benign and Malignant Breast Diseases. Luis M. Sánchez, Francisco Vizoso, Irene Díez-Itza, and Carlos López-Otin.


* 154 Effect of *ω*-3 and *ω*-6 Fatty Acids on Transformation of Cultured Cells by Irradiation and Transfection. Marelyuki Takahashi, Marek Przetakiewicz, Augustine Ong, Carmia Borek, and John M. Lowenstein.

---

**Immunology**


---

**Carcinogenesis**


* 202 Specific Binding to Protein Kinase C by Ingenol and Its Induction of Biological Responses. Clare M. Hasler, Geza Acs, and Peter M. Blumberg.

---

**Endocrinology**


---

**Molecular Biology and Genetics**

* 5 Activation of the gadd153 Promoter by Genotoxic Agents: A Rapid and Specific Response to DNA Damage. Jennifer D. Luethy and Nikki J. Holbrook.

* 11 Abundance of the Primary Transcript and Its Processed Product of Growth-related Genes in Normal and Leukemic Cells during Proliferation and Differentiation. Sergio Ferrari, Enrico Tagliafico, Rossella Manfredini, Alexis Grande, Elena Rossi, Patrizia Zucchini, Giuseppe Torelli, and Umberto Torelli.

---

**Preclinical Pharmacology and Experimental Therapeutics**


* 36 Intracellular Metabolism of S-Formyl Tetrahydrofolate in Human Breast and Colon Cell Lines. Donna M. Boarman and Carmen J. Allegre.


---

* Indicates studies using human-derived material.
*101 Preclinical Evaluation of Bryostatin as an Anticancer Agent against Several Murine Tumor Cell Lines: In Vitro versus In Vivo Activity. Ronald L. Hornung, John W. Pearson, Margaret Beckwith, and Dan L. Longo.


138 Melphalan Penetration of the Blood-Brain Barrier via the Neutral Amino Acid Transporter in Tumor-bearing Brain. Eain M. Cornford, Deborah Young, James W. Paxton, Graeme J. Finlay, William R. Wilson, and William M. Partridge.


*209 Relative Activity of Structural Analogues of Amsacrine against Human Leukemia Cell Lines Containing Amsacrine-sensitive or -resistant Forms of Topoisomerase II: Use of Computer Simulations in New Drug Development. Leonard A. Zwelling, Michael J. Mitchell, Patricia Satipunwachya, Janice Mayes, Elizabeth Altschuler, Michael Hinds, and Bruce C. Baguley.

Tumor Biology


168 Morphological Reversion of sis-transformed NIH3T3 Cells by Trichostatin A. Kenji Sugita, Kenzo Koizumi, and Hiroshi Yoshida.

MOLECULAR ONCOLOGY AS A BASIS FOR NEW STRATEGIES IN CANCER THERAPY

Second Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association
Sheraton Waikiki Hotel, Honolulu, HI
February 10-14, 1992

SCIENTIFIC PROGRAM COMMITTEE

AACR
I. BERNARD WEINSTEIN / New York
Co-Chairperson
BRUCE A. CHABNER / Bethesda
YUNG-CHI CHENG / New Haven
HAROLD L. MOSES / Nashville
ANNA MARIE SKALKA / Philadelphia

JCA
SUSUMU NISHIMURA / Tokyo
Co-Chairperson
YOSHIYUKI HASHIMOTO / Tohoku
TADAO KAKIZOE / Tokyo
HIROSHI KOBAYASHI / Sapporo
TOSHIKAZU NAKAMURA / Kyushu
TAKAO SEKIYA / Tokyo
MASANORI SHIMOYAMA / Tokyo
HARUO SUGANO / Tokyo
TAKASHI SUGIMURA / Tokyo
SHOZO TAKAYAMA / Tokyo
MASAAKI TERADA / Tokyo
KUMAO TOYOSHIMA / Osaka
TAKASHI TSURUO / Tokyo

SCIENTIFIC PROGRAM

Recent Advances in Chemotherapy and Drug Resistance
ENRICO MIHICH / Buffalo
MESANORI SHIMOYAMA / Tokyo
KURT W. KOHN / Bethesda
JUDAH M. FOLKMAN / Boston
MICHAEL A. GOTTESMAN / Bethesda
TAKASHI TSURUO / Tokyo
SUSAN BAND HORWITZ / New York
HIROSHI MAEDA / Kumamoto

Molecular Targeting Approaches
V. CRAIG JORDAN / Madison
YOSHIKU HASHIMOTO / Tohoku
TERUKIYO SEPPU / Tokyo
SHIN YONEHARA / Tokyo
PAUL S. MILLER / Baltimore
JOSEPH R. BERTINO / New York
TOSHI O TAHASHI / Kyoto

Molecular Genetics, Models, and Strategies
MICHAEL BLAESER / Bethesda
FUMIMARU TAKAKU / Tokyo
YOSHIHIDE HAYASHIZAKI / Osaka
KUNITADA SHIMOTOHNO / Tokyo
TAKAO SEKIYA / Tokyo
MOTOYA KATSUKI / Isehara
ARGIRIS EFSTRATIADIS / New York

Overview and Summary
YUNG-CHI CHENG / New Haven

Scientists are encouraged to submit abstracts of papers for consideration for poster sessions. Persons in the Americas and countries other than Japan may obtain additional information from the AACR Office.

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483 USA
Telephone: (215) 440-9300
FAX: (215) 440-9313

Japanese Cancer Association
National Cancer Center
5-1-1 Tsukiji, Chuo-ku
Tokyo, 104 JAPAN
The Princess Takamatsu Symposia have achieved worldwide renown for both the quality of the scientific presentations and the stature of the participating scientists. The ambience of the Symposia is unique, combining a mixture of Japanese traditional customs and Western-style open discussion. The Symposia proceedings are published annually and are important additions to the cancer research literature. Social and cultural highlights of the Symposia are the formal openings, presided over by Princess Takamatsu, and the closing evening receptions at the residence of the Princess. That a member of the Royal Family has so totally engaged herself in the public and humanitarian cause of support for cancer research is a tribute to the Princess and to the Royal Family.

The picture in the lower right-hand corner of this page is of Her Imperial Highness in November 1990 in the Imperial court costume worn on the occasion of the Emperor’s enthronement. The costume, derived from the 8th century style, was the principal garment of nobility and is known as the “hirosode” (broad sleeves).

The cancer research community, as a beneficiary of her patronage and of the sponsorship of the Princess Takamatsu Cancer Research Fund, is deeply appreciative of Her Imperial Highness for supporting and sustaining the Fund through her dedication, perseverance, and commitment to the eradication of cancer. The Princess Takamatsu Cancer Research Fund Symposia, while continuously maintaining a high quality of scientific content, have been graced by Her Imperial Highness and by the knowledge of her devotion to their purpose.

We thank Her Imperial Highness for helping to nurture interest in the quest for knowledge on the nature of cancer. Ultimately, her dedication will ensure that Princess Takamatsu is honored and respected both as Princess of the Royal House of Japan and as a great lady of the world.

H. V. Gelboin
T. Kakefuda

It is a great pleasure to pay tribute on this issue’s cover to Her Imperial Highness, Princess Takamatsu, of the Royal Family of Japan. Princess Takamatsu has devoted much of her life’s work to alleviating the scourge of cancer, and towards this noble goal the Princess Takamatsu Cancer Research Fund was established in 1968. It evolved from the Nadeshiko-kai, founded by Princess Takamatsu and her classmates at Joshi Gakushuin School for Girls in 1933 shortly after cancer took the life of her mother. At that time, the Princess became the patron of many charitable causes in support of cancer research. Through her efforts, there has been a large increase in public awareness and concern for the elimination of cancer through the support of cancer research.

Since its inception, the Princess Takamatsu Cancer Research Fund has sponsored twenty-one annual International Symposia related to cancer research; established the IBM-Princess Takamatsu Cancer Research Fund Lectureship to bring internationally renowned cancer researchers to Japan; provided grants for the support of cancer research and travel for Japanese scientists; and awarded prizes to Japanese scientists for accomplishments of major distinction. Recently, the Nakahara Memorial Senior Fellowship Program for retired scientists was launched to provide these investigators with opportunities to continue to actively contribute in various fields of cancer research.

The Foundation has benefitted from the key contributions of advisory panels of expert scientists. The domestic and international activities of the Foundation have been a strong and positive force for the promotion of cancer research in Japan and were particularly helpful during the difficult period of recovery following World War II. The late Waro Nakahara deserves mention for organizing the First International Symposium in 1970.